134b The Effects of Ppar Modulation on Cox-2-Depedent Inflammation and Apoptosis in Shear-Activated Chondrocytes: a Role in Arthritis

Zachary Healy1, Norman Lee2, Paul Talalay3, and Konstantinos Konstantopoulos1. (1) Chemical & Biomolecular Engineering, Johns Hopkins University, 3400 N. Charles Street, Maryland Hall Room 223, Baltimore, MD 21218, (2) Molecular Biololgy and Functional Genomics, The Institute for Genomic Research, 9700 Medical Center Drive, Rockville, MD 21085, (3) Pharmacology, Director of the Laboratory for Molecular Sciences, Johns Hopkins University - School of Medicine, 725 N Wolfe Street, Baltimore, MD 21205

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that regulate lipid metabolism, glucose homeostasis, and cell proliferation, and are thought to modulate inflammation. We have previously shown that COX-2 expression, inflammation and apoptosis preferentially occur in areas of cartilage exposed to prolong periods of high laminar shear flow (20 dyn/cm2, 48 hrs). Using cDNA microarray technology coupled with novel bioinformatics tools, we observed that high shear flow repressed PPARα and induced PPAR&beta/δ mRNA/protein expression and transcriptional activity. This PPAR activity modulation was eliminated in the presence of COX-2 inhibitors, thus identifying the PPAR family as likely downsteam targets of pro-inflammatory COX-2 signaling. The use of PPARα and PPARγ but not PPAR&beta/δ selective agonists reduced the shear-induced COX-2 expression and activity and increased anti-inflammatory phase 2 enzyme activity, potentially through feedback by inhibiting COX-2-dependent signaling. Alternatively, the use of shRNAs targeting PPAR&beta/&delta diminished shear-induced inflammatory signaling, and significantly increased both PPARα and PPARγ expression and activity, indicating potential cross-talk between the PPAR family members. Furthermore, PPARα or PPARγ agonists or PPAR&beta/δ knockdown significantly reduced caspase-9-dependent apoptosis in sheared chondrocytes. PPARα and PPARγ agonists therefore represent novel therapeutic tool for the treatment of inflammatory disease such as arthritis.